Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 211 articles:
HTML format
Text format



Single Articles


    April 2019
  1. VICKERS AD, Winfree KB, Cuyun Carter G, Kiiskinen U, et al
    Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2019;19:353.
    PubMed     Text format     Abstract available


  2. SUMODHEE S, Bondiau PY, Poudenx M, Cohen C, et al
    Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    BMC Cancer. 2019;19:305.
    PubMed     Text format     Abstract available


  3. FURUGAKI K, Mochizuki M, Kohno M, Shu S, et al
    Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    BMC Cancer. 2019;19:301.
    PubMed     Text format     Abstract available


  4. CHO YJ, Cho YM, Kim SH, Shin KH, et al
    Clinical analysis of patients with skeletal metastasis of lung cancer.
    BMC Cancer. 2019;19:303.
    PubMed     Text format     Abstract available


    March 2019
  5. CHEN Y, Tsang YS, Chou X, Hu J, et al
    A lung cancer patient with deep vein thrombosis:a case report and literature review.
    BMC Cancer. 2019;19:285.
    PubMed     Text format     Abstract available


  6. YING J, Zhou D, Gu T, Huang J, et al
    Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    BMC Cancer. 2019;19:288.
    PubMed     Text format     Abstract available


  7. ZHAO P, Wu J, Lu F, Peng X, et al
    Correction to: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:269.
    PubMed     Text format     Abstract available


  8. YANG LH, Han Y, Li G, Xu HT, et al
    Correction to: Axin gene methylation status correlates with radiosensitivity of lung cancer cells.
    BMC Cancer. 2019;19:268.
    PubMed     Text format     Abstract available


  9. SONE K, Oguri T, Uemura T, Takeuchi A, et al
    Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    BMC Cancer. 2019;19:246.
    PubMed     Text format     Abstract available


  10. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
    BMC Cancer. 2019;19:241.
    PubMed     Text format     Abstract available


  11. ZHANG C, Mao M, Guo X, Cui P, et al
    Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer.
    BMC Cancer. 2019;19:238.
    PubMed     Text format     Abstract available


  12. ESFANDI F, Taheri M, Omrani MD, Shadmehr MB, et al
    Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues.
    BMC Cancer. 2019;19:222.
    PubMed     Text format     Abstract available


  13. WOOD R, Taylor-Stokes G
    Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
    BMC Cancer. 2019;19:214.
    PubMed     Text format     Abstract available


  14. LU L, Liu Q, Wang P, Wu Y, et al
    MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway.
    BMC Cancer. 2019;19:209.
    PubMed     Text format     Abstract available


  15. ZHAO P, Wu J, Lu F, Peng X, et al
    The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:201.
    PubMed     Text format     Abstract available


    February 2019
  16. BERGAMINO M, Rullan AJ, Saigi M, Peiro I, et al
    Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    BMC Cancer. 2019;19:165.
    PubMed     Text format     Abstract available


  17. SHIRASAWA M, Fukui T, Kusuhara S, Hiyoshi Y, et al
    Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    BMC Cancer. 2019;19:163.
    PubMed     Text format     Abstract available


  18. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Text format     Abstract available


  19. D'ALMEIDA O, Mothar O, Bondzie EA, Lieumo Y, et al
    Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
    BMC Cancer. 2019;19:136.
    PubMed     Text format     Abstract available


    January 2019
  20. IMAKITA T, Matsumoto H, Hirano K, Morisawa T, et al
    Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    BMC Cancer. 2019;19:105.
    PubMed     Text format     Abstract available


  21. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Text format     Abstract available


  22. CEA SORIANO L, Zong J, Garcia Rodriguez LA
    Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom.
    BMC Cancer. 2019;19:91.
    PubMed     Text format     Abstract available


  23. ROMINE PE, Martins RG, Eaton KD, Wood DE, et al
    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    BMC Cancer. 2019;19:70.
    PubMed     Text format     Abstract available


  24. CASSIM S, Chepulis L, Keenan R, Kidd J, et al
    Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review.
    BMC Cancer. 2019;19:25.
    PubMed     Text format     Abstract available


  25. YAN S, Sun R, Wu S, Jin T, et al
    Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.
    BMC Cancer. 2019;19:35.
    PubMed     Text format     Abstract available


  26. SIRIWARDHANA C, Khadka VS, Chen JJ, Deng Y, et al
    Development of a miRNA-seq based prognostic signature in lung adenocarcinoma.
    BMC Cancer. 2019;19:34.
    PubMed     Text format     Abstract available


  27. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Text format     Abstract available


  28. WU Z, Wang Q, Wu C, Zhan T, et al
    Three-port single-intercostal versus multiple-intercostal thoracoscopic lobectomy for the treatment of lung cancer: a propensity-matched analysis.
    BMC Cancer. 2019;19:8.
    PubMed     Text format     Abstract available


  29. WERUTSKY G, Hochhegger B, Lopes de Figueiredo Pinto JA, Martinez-Mesa J, et al
    PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
    BMC Cancer. 2019;19:5.
    PubMed     Text format     Abstract available


    December 2018
  30. GUO HQ, Jia J, Zhao LL, Zhao H, et al
    Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2018;18:1277.
    PubMed     Text format     Abstract available


  31. REMEN T, Pintos J, Abrahamowicz M, Siemiatycki J, et al
    Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal.
    BMC Cancer. 2018;18:1275.
    PubMed     Text format     Abstract available


  32. SUN H, Gao D
    Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372.
    BMC Cancer. 2018;18:1252.
    PubMed     Text format     Abstract available


  33. YOSHIMURA A, Yamada T, Okura N, Takeda T, et al
    The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1241.
    PubMed     Text format     Abstract available


  34. TSUTANI Y, Miyata Y, Masuda T, Fujitaka K, et al
    Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    BMC Cancer. 2018;18:1231.
    PubMed     Text format     Abstract available


  35. NG KEE KWONG F, Nicholson AG, Pavlidis S, Adcock IM, et al
    PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
    BMC Cancer. 2018;18:1238.
    PubMed     Text format     Abstract available


  36. HUANG Y, Wei S, Jiang N, Zhang L, et al
    The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1235.
    PubMed     Text format     Abstract available


  37. LEE JS, Hur JY, Kim IA, Kim HJ, et al
    Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    BMC Cancer. 2018;18:1236.
    PubMed     Text format     Abstract available


  38. KIM EY, Kim A, Lee G, Lee H, et al
    Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
    BMC Cancer. 2018;18:1221.
    PubMed     Text format     Abstract available


  39. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Text format     Abstract available


    November 2018
  40. SINGH AK, Hennon M, Ma SJ, Demmy TL, et al
    A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
    BMC Cancer. 2018;18:1183.
    PubMed     Text format     Abstract available


  41. SCHWARTZ RM, Lieberman-Cribbin W, Wolf A, Flores RM, et al
    Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
    BMC Cancer. 2018;18:1188.
    PubMed     Text format     Abstract available


  42. LIU K, Xu SH, Chen Z, Zeng QX, et al
    TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90alpha/uPA/MMP2 signaling pathway.
    BMC Cancer. 2018;18:1167.
    PubMed     Text format     Abstract available


  43. CHEN RL, Zhao J, Zhang XC, Lou NN, et al
    Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    BMC Cancer. 2018;18:1171.
    PubMed     Text format     Abstract available


  44. DE MOL M, Visser S, Aerts JGJV, Lodder P, et al
    Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients
    BMC Cancer. 2018;18:1173.
    PubMed     Text format     Abstract available


  45. VOLLBRECHT C, Lenze D, Hummel M, Lehmann A, et al
    RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    BMC Cancer. 2018;18:1158.
    PubMed     Text format     Abstract available


  46. RICH A, Baldwin D, Alfageme I, Beckett P, et al
    Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.
    BMC Cancer. 2018;18:1144.
    PubMed     Text format     Abstract available


  47. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Text format     Abstract available


  48. YOSHIDA R, Sasaki T, Umekage Y, Tanno S, et al
    Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
    BMC Cancer. 2018;18:1136.
    PubMed     Text format     Abstract available


  49. ZANELLI M, Mengoli MC, Del Sordo R, Cagini A, et al
    Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.
    BMC Cancer. 2018;18:1115.
    PubMed     Text format     Abstract available


  50. SEIGNEURIN A, Delafosse P, Tretarre B, Woronoff AS, et al
    Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.
    BMC Cancer. 2018;18:1091.
    PubMed     Text format     Abstract available


  51. KIM EJ, Ock M, Kim KP, Jung NH, et al
    Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.
    BMC Cancer. 2018;18:1081.
    PubMed     Text format     Abstract available


  52. PU X, Wu L, Su D, Mao W, et al
    Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
    BMC Cancer. 2018;18:1082.
    PubMed     Text format     Abstract available


  53. WANG X, Yin C, Su S, Li X, et al
    Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    BMC Cancer. 2018;18:1067.
    PubMed     Text format     Abstract available


  54. ZHENG LP, Chen LY, Liao XY, Xu ZH, et al
    Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
    BMC Cancer. 2018;18:1070.
    PubMed     Text format     Abstract available


    October 2018
  55. YI YS, Ban WH, Sohng KY
    Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    BMC Cancer. 2018;18:1053.
    PubMed     Text format     Abstract available


  56. IEZZI A, Caiola E, Scagliotti A, Broggini M, et al
    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.
    BMC Cancer. 2018;18:1028.
    PubMed     Text format     Abstract available


  57. ZHOU F, Ma W, Li W, Ni H, et al
    Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    BMC Cancer. 2018;18:1033.
    PubMed     Text format     Abstract available


  58. SCHERPEREEL A, Durand-Zaleski I, Cotte FE, Fernandes J, et al
    Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
    BMC Cancer. 2018;18:1013.
    PubMed     Text format     Abstract available


  59. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Text format     Abstract available


  60. LAVACCHI D, Nobili S, Brugia M, Paderi A, et al
    A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
    BMC Cancer. 2018;18:1024.
    PubMed     Text format     Abstract available


  61. HAI Y, Chen N, Wu W, Wang Z, et al
    High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy.
    BMC Cancer. 2018;18:1011.
    PubMed     Text format     Abstract available


  62. GUO Y, Wang X, Xiao J, Xu Y, et al
    Lung squamous cell carcinoma with solitary ocular metastasis and its successful treatment with thoracic surgery and chemotherapy: an interesting and rare case report.
    BMC Cancer. 2018;18:1004.
    PubMed     Text format     Abstract available


  63. XU J, Guo W, Xie L
    Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
    BMC Cancer. 2018;18:987.
    PubMed     Text format     Abstract available


  64. KIM MK, Yee J, Cho YS, Jang HW, et al
    Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
    BMC Cancer. 2018;18:988.
    PubMed     Text format     Abstract available


  65. LIU L, Shi M, Wang Z, Lu H, et al
    A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
    BMC Cancer. 2018;18:966.
    PubMed     Text format     Abstract available


  66. QIN RS, Zhang ZH, Zhu NP, Chen F, et al
    Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    BMC Cancer. 2018;18:967.
    PubMed     Text format     Abstract available


  67. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Text format     Abstract available


  68. ISAKA T, Nakayama H, Ito H, Yokose T, et al
    Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    BMC Cancer. 2018;18:959.
    PubMed     Text format     Abstract available


  69. TACHIHARA M, Negoro S, Inoue T, Tamiya M, et al
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    BMC Cancer. 2018;18:946.
    PubMed     Text format     Abstract available


  70. SABATH B, Muhammad HA, Balagani A, Ost DE, et al
    Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
    BMC Cancer. 2018;18:937.
    PubMed     Text format     Abstract available


    September 2018
  71. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Engaging the older cancer patient; Patient Activation through Counseling, Exercise and Mobilization - Pancreatic, Biliary tract and Lung cancer (PACE-Mobil-PBL) - study protocol of a randomized controlled trial.
    BMC Cancer. 2018;18:934.
    PubMed     Text format     Abstract available


  72. ANDRIANI F, Landoni E, Mensah M, Facchinetti F, et al
    Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.
    BMC Cancer. 2018;18:899.
    PubMed     Text format     Abstract available


  73. YIN Z, Cui Z, Li H, Li J, et al
    Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China.
    BMC Cancer. 2018;18:893.
    PubMed     Text format     Abstract available


  74. BENBRAHIM Z, Antonia T, Mellas N
    EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:891.
    PubMed     Text format     Abstract available


  75. VANHOVE K, Giesen P, Owokotomo OE, Mesotten L, et al
    The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.
    BMC Cancer. 2018;18:868.
    PubMed     Text format     Abstract available


    August 2018
  76. KIM Y, Pierce CM, Robinson LA
    Impact of viral presence in tumor on gene expression in non-small cell lung cancer.
    BMC Cancer. 2018;18:843.
    PubMed     Text format     Abstract available


  77. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Text format     Abstract available


  78. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Text format     Abstract available


  79. VAUGHN CP, Costa JL, Feilotter HE, Petraroli R, et al
    Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    BMC Cancer. 2018;18:828.
    PubMed     Text format     Abstract available


  80. KIM MC, Hwang SH, Kim NY, Lee HS, et al
    Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.
    BMC Cancer. 2018;18:819.
    PubMed     Text format     Abstract available


  81. XU F, Ren X, Chen Y, Li Q, et al
    Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2018;18:808.
    PubMed     Text format     Abstract available


  82. HUANG H, Tong TT, Yau LF, Chen CY, et al
    LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain.
    BMC Cancer. 2018;18:799.
    PubMed     Text format     Abstract available


  83. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
    Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    BMC Cancer. 2018;18:796.
    PubMed     Text format     Abstract available


  84. ZHANG W, Wei Y, Yu D, Xu J, et al
    Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2018;18:780.
    PubMed     Text format     Abstract available


    July 2018
  85. KIM IA, Lee JS, Kim HJ, Kim WS, et al
    Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    BMC Cancer. 2018;18:768.
    PubMed     Text format     Abstract available


  86. SAHIN IH, Elias H, Chou JF, Capanu M, et al
    Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
    BMC Cancer. 2018;18:769.
    PubMed     Text format     Abstract available


  87. BORM KJ, Oechsner M, Wiegandt M, Hofmeister A, et al
    Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data.
    BMC Cancer. 2018;18:760.
    PubMed     Text format     Abstract available


  88. BUTCHER K, Kannappan V, Kilari RS, Morris MR, et al
    Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
    BMC Cancer. 2018;18:753.
    PubMed     Text format     Abstract available


  89. MAZZA D, Lin X, Walter FM, Young JM, et al
    The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds.
    BMC Cancer. 2018;18:754.
    PubMed     Text format     Abstract available


  90. BERG J, Halvorsen AR, Bengtson MB, Tasken KA, et al
    Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
    BMC Cancer. 2018;18:739.
    PubMed     Text format     Abstract available


  91. ZACHARIAS M, Brcic L, Eidenhammer S, Popper H, et al
    Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated.
    BMC Cancer. 2018;18:717.
    PubMed     Text format     Abstract available


  92. SHENG Y, Xu M, Li C, Xiong Y, et al
    Nm23-H1 is involved in the repair of ionizing radiation-induced DNA double-strand breaks in the A549 lung cancer cell line.
    BMC Cancer. 2018;18:710.
    PubMed     Text format     Abstract available


    June 2018
  93. WANG Y, Qu X, Kam NW, Wang K, et al
    An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.
    BMC Cancer. 2018;18:692.
    PubMed     Text format     Abstract available


  94. LI X, Zhou Q, Wang X, Su S, et al
    The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes.
    BMC Cancer. 2018;18:683.
    PubMed     Text format     Abstract available


  95. TIAN X, Ma J, Wang T, Tian J, et al
    Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer.
    BMC Cancer. 2018;18:660.
    PubMed     Text format     Abstract available


  96. HOU X, Gong R, Zhan J, Zhou T, et al
    p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:641.
    PubMed     Text format     Abstract available


  97. ZHU H, Zhang S
    Body mass index and lung cancer risk in never smokers: a meta-analysis.
    BMC Cancer. 2018;18:635.
    PubMed     Text format     Abstract available


    May 2018
  98. MARINGE C, Pashayan N, Rubio FJ, Ploubidis G, et al
    Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?
    BMC Cancer. 2018;18:615.
    PubMed     Text format     Abstract available


  99. SHINOZAKI T, Iwami E, Ikemura S, Matsuzaki T, et al
    A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
    BMC Cancer. 2018;18:620.
    PubMed     Text format     Abstract available


  100. ZENG J, Zhang H, Tan Y, Sun C, et al
    Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:611.
    PubMed     Text format     Abstract available


  101. ZHENG J, Jia L, Mori S, Kodama T, et al
    Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes.
    BMC Cancer. 2018;18:608.
    PubMed     Text format     Abstract available


  102. WEI X, Zhang K, Qin H, Zhu J, et al
    GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma.
    BMC Cancer. 2018;18:600.
    PubMed     Text format     Abstract available


  103. MARKOCZY Z, Sarosi V, Kudaba I, Galffy G, et al
    Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    BMC Cancer. 2018;18:598.
    PubMed     Text format     Abstract available


  104. LI H, Huang N, Zhu W, Wu J, et al
    Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    BMC Cancer. 2018;18:579.
    PubMed     Text format     Abstract available


  105. ZHOU W, Chen X, Hu Q, Chen X, et al
    Galectin-3 activates TLR4/NF-kappaB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
    BMC Cancer. 2018;18:580.
    PubMed     Text format     Abstract available


  106. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Text format     Abstract available


  107. LIMVIPHUVADH V, Tan CS, Konishi F, Jenjaroenpun P, et al
    Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
    BMC Cancer. 2018;18:555.
    PubMed     Text format     Abstract available


  108. LI Y, Chen G, Chen H, Wen S, et al
    Spontaneous renal hemorrhage secondary to choriocarcinoma in a man with congenital hypospadias and cryptorchidism: a case report and literature review.
    BMC Cancer. 2018;18:543.
    PubMed     Text format     Abstract available


  109. EZZELDIN N, El-Lebedy D, Darwish A, El Bastawisy A, et al
    Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
    BMC Cancer. 2018;18:525.
    PubMed     Text format     Abstract available


  110. QUAIFE SL, Vrinten C, Ruparel M, Janes SM, et al
    Smokers' interest in a lung cancer screening programme: a national survey in England.
    BMC Cancer. 2018;18:497.
    PubMed     Text format     Abstract available


  111. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Text format     Abstract available


    April 2018
  112. BLUM W, Pecze L, Rodriguez JW, Steinauer M, et al
    Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
    BMC Cancer. 2018;18:475.
    PubMed     Text format     Abstract available


  113. MORRISON BJ, Steel JC, Morris JC
    Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    BMC Cancer. 2018;18:469.
    PubMed     Text format     Abstract available


  114. HE F, Xiao RD, Lin T, Xiong WM, et al
    Dietary patterns, BCMO1 polymorphisms, and primary lung cancer risk in a Han Chinese population: a case-control study in Southeast China.
    BMC Cancer. 2018;18:445.
    PubMed     Text format     Abstract available


  115. MISHRA DK, Miller RA, Pence KA, Kim MP, et al
    Small cell and non small cell lung cancer form metastasis on cellular 4D lung model.
    BMC Cancer. 2018;18:441.
    PubMed     Text format     Abstract available


  116. GIGER-PABST U, Demtroder C, Falkenstein TA, Ouaissi M, et al
    Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
    BMC Cancer. 2018;18:442.
    PubMed     Text format     Abstract available


  117. ABBAS HHK, Alhamoudi KMH, Evans MD, Jones GDD, et al
    MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    BMC Cancer. 2018;18:423.
    PubMed     Text format     Abstract available


  118. DHONT L, Pintilie M, Kaufman E, Navab R, et al
    Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).
    BMC Cancer. 2018;18:429.
    PubMed     Text format     Abstract available


  119. AI X, Mao F, Shen S, Shentu Y, et al
    Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.
    BMC Cancer. 2018;18:407.
    PubMed     Text format     Abstract available


  120. HE W, Zhang H, Wang Y, Zhou Y, et al
    CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
    BMC Cancer. 2018;18:400.
    PubMed     Text format     Abstract available


  121. VANNIMENUS C, Bricout H, Le Rouzic O, Mouawad F, et al
    Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study.
    BMC Cancer. 2018;18:372.
    PubMed     Text format     Abstract available


  122. THRIUMANI R, Zakaria A, Hashim YZH, Jeffree AI, et al
    A study on volatile organic compounds emitted by in-vitro lung cancer cultured cells using gas sensor array and SPME-GCMS.
    BMC Cancer. 2018;18:362.
    PubMed     Text format     Abstract available


    March 2018
  123. TAN PT, Aziz MIA, Pearce F, Lim WT, et al
    Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    BMC Cancer. 2018;18:352.
    PubMed     Text format     Abstract available


  124. BRUECKL WM, Achenbach HJ, Ficker JH, Schuette W, et al
    Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    BMC Cancer. 2018;18:333.
    PubMed     Text format     Abstract available


  125. NAGAMATSU Y, Oze I, Aoe K, Hotta K, et al
    Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
    BMC Cancer. 2018;18:350.
    PubMed     Text format     Abstract available


  126. WANG Y, Zhang S, Wu F, Zhao J, et al
    Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    BMC Cancer. 2018;18:326.
    PubMed     Text format     Abstract available


  127. MAMBETSARIEV I, Vora L, Yu KW, Salgia R, et al
    Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
    BMC Cancer. 2018;18:314.
    PubMed     Text format     Abstract available


  128. FIDLER MJ, Fhied CL, Roder J, Basu S, et al
    The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    BMC Cancer. 2018;18:310.
    PubMed     Text format     Abstract available


  129. LYNCH JA, Berse B, Rabb M, Mosquin P, et al
    Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
    BMC Cancer. 2018;18:306.
    PubMed     Text format     Abstract available


  130. HAKOZAKI T, Okuma Y, Kashima J
    Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
    BMC Cancer. 2018;18:302.
    PubMed     Text format     Abstract available


  131. BRIZZI MP, La Salvia A, Tampellini M, Sonetto C, et al
    Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
    BMC Cancer. 2018;18:311.
    PubMed     Text format     Abstract available


  132. YORITA K, Tsuji K, Takano Y, Kuroda N, et al
    Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report.
    BMC Cancer. 2018;18:300.
    PubMed     Text format     Abstract available


  133. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Text format     Abstract available


  134. YAO D, Zhang L, Wu PL, Gu XL, et al
    Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.
    BMC Cancer. 2018;18:281.
    PubMed     Text format     Abstract available


  135. RYSKA A, Berzinec P, Brcic L, Cufer T, et al
    NSCLC molecular testing in Central and Eastern European countries.
    BMC Cancer. 2018;18:269.
    PubMed     Text format     Abstract available


  136. WANG G, Guo C, Zhao H, Pan Z, et al
    TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    BMC Cancer. 2018;18:260.
    PubMed     Text format     Abstract available


  137. JIN BF, Yang F, Ying XM, Gong L, et al
    Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    BMC Cancer. 2018;18:259.
    PubMed     Text format     Abstract available


  138. LEE DW, Lee KH, Kim HJ, Kim TY, et al
    A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    BMC Cancer. 2018;18:252.
    PubMed     Text format     Abstract available


  139. IKEDA S, Kato T, Ogura T, Sekine A, et al
    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thorac
    BMC Cancer. 2018;18:241.
    PubMed     Text format     Abstract available


    February 2018
  140. BROGDEN KA, Parashar D, Hallier AR, Braun T, et al
    Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer. 2018;18:225.
    PubMed     Text format     Abstract available


  141. SANIKINI H, Yuan JM, Butler LM, Koh WP, et al
    Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies.
    BMC Cancer. 2018;18:220.
    PubMed     Text format     Abstract available


  142. DE FONSEKA D, Arnold DT, Stadon L, Morley A, et al
    A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    BMC Cancer. 2018;18:199.
    PubMed     Text format     Abstract available


  143. DEMUTH C, Madsen AT, Weber B, Wu L, et al
    The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    BMC Cancer. 2018;18:191.
    PubMed     Text format     Abstract available


  144. CHU GCW, Lazare K, Sullivan F
    Serum and blood based biomarkers for lung cancer screening: a systematic review.
    BMC Cancer. 2018;18:181.
    PubMed     Text format     Abstract available


  145. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Text format     Abstract available


  146. OLIVIER C, Grosbois JM, Cortot AB, Peres S, et al
    Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
    BMC Cancer. 2018;18:178.
    PubMed     Text format     Abstract available


  147. MERVAI Z, Egedi K, Kovalszky I, Baghy K, et al
    Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
    BMC Cancer. 2018;18:157.
    PubMed     Text format     Abstract available


  148. WANG ZF, Ren SX, Li W, Gao GH, et al
    Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:148.
    PubMed     Text format     Abstract available


  149. SCHUETTE W, Schirmacher P, Eberhardt WEE, Dietel M, et al
    Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    BMC Cancer. 2018;18:135.
    PubMed     Text format     Abstract available


    January 2018
  150. OU JY, Fowler B, Ding Q, Kirchhoff AC, et al
    A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population.
    BMC Cancer. 2018;18:115.
    PubMed     Text format     Abstract available


  151. ARRIOLA E, Garcia Gomez R, Diz P, Majem M, et al
    Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    BMC Cancer. 2018;18:106.
    PubMed     Text format     Abstract available


  152. NARUMI Y, Yoshida R, Minami Y, Yamamoto Y, et al
    Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    BMC Cancer. 2018;18:95.
    PubMed     Text format     Abstract available


  153. MOKHLES S, Nuyttens JJME, de Mol M, Aerts JGJV, et al
    Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making.
    BMC Cancer. 2018;18:79.
    PubMed     Text format     Abstract available


  154. WU N, Ren D, Li S, Ma W, et al
    RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
    BMC Cancer. 2018;18:67.
    PubMed     Text format     Abstract available


  155. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Text format     Abstract available


  156. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Text format     Abstract available


  157. QU TT, Chen F, Wang J, Zhang YJ, et al
    PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.
    BMC Cancer. 2018;18:27.
    PubMed     Text format     Abstract available


  158. ZHOU J, Zheng J, Zhang X, Zhao J, et al
    Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    BMC Cancer. 2018;18:10.
    PubMed     Text format     Abstract available


  159. KANEDA T, Yoshioka H, Tamiya M, Tamiya A, et al
    Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    BMC Cancer. 2018;18:6.
    PubMed     Text format     Abstract available


    December 2017
  160. LIU D, Huang Y, Li L, Song J, et al
    High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    BMC Cancer. 2017;17:882.
    PubMed     Text format     Abstract available


  161. WANG D, Haley JD, Thompson P
    Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    BMC Cancer. 2017;17:830.
    PubMed     Text format     Abstract available


  162. BLANCO-PRIETO S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al
    Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.
    BMC Cancer. 2017;17:823.
    PubMed     Text format     Abstract available


    November 2017
  163. IKEDA S, Yoshioka H, Ikeo S, Morita M, et al
    Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    BMC Cancer. 2017;17:797.
    PubMed     Text format     Abstract available


  164. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
    BMC Cancer. 2017;17:800.
    PubMed     Text format     Abstract available


  165. HIGUCHI Y, Motoki T, Ishida H, Kanamitsu K, et al
    Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    BMC Cancer. 2017;17:775.
    PubMed     Text format     Abstract available


  166. KRISHNASWAMY S, Mohammed AK, Tripathi G, Alokail MS, et al
    Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    BMC Cancer. 2017;17:738.
    PubMed     Text format     Abstract available


  167. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Text format     Abstract available


  168. WANG T, Chen X, Qiao W, Kong L, et al
    Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer.
    BMC Cancer. 2017;17:719.
    PubMed     Text format     Abstract available


    October 2017
  169. TANAKA H, Taima K, Morimoto T, Tanaka Y, et al
    A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    BMC Cancer. 2017;17:683.
    PubMed     Text format     Abstract available


    September 2017
  170. EDBROOKE L, Aranda S, Granger CL, McDonald CF, et al
    Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer - protocol for a phase II randomised controlled trial.
    BMC Cancer. 2017;17:663.
    PubMed     Text format     Abstract available


  171. JIN R, Chen X, Han D, Luo X, et al
    Clusterin modulates transdifferentiation of non-small-cell lung cancer.
    BMC Cancer. 2017;17:661.
    PubMed     Text format     Abstract available


  172. URUSHIYAMA H, Jo T, Yasunaga H, Yamauchi Y, et al
    Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis: a retrospective observational study with use of a national database in Japan.
    BMC Cancer. 2017;17:613.
    PubMed     Text format     Abstract available


    August 2017
  173. WANG X, Su S, Li S, Bao H, et al
    Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China.
    BMC Cancer. 2017;17:603.
    PubMed     Text format     Abstract available


  174. AARELEID T, Zimmermann ML, Baburin A, Innos K, et al
    Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study.
    BMC Cancer. 2017;17:596.
    PubMed     Text format     Abstract available


  175. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Text format     Abstract available


  176. HATA Y, Kiribayashi T, Kishi K, Nagashima M, et al
    Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
    BMC Cancer. 2017;17:581.
    PubMed     Text format     Abstract available


  177. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2017;17:571.
    PubMed     Text format     Abstract available


  178. SZTANKAY M, Giesinger JM, Zabernigg A, Krempler E, et al
    Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
    BMC Cancer. 2017;17:565.
    PubMed     Text format     Abstract available


  179. LEE YS, Nam HS, Lim JH, Kim JS, et al
    Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    BMC Cancer. 2017;17:557.
    PubMed     Text format     Abstract available


    July 2017
  180. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Text format     Abstract available


  181. WANG Q, Cheng Y, Wang Y, Fan Y, et al
    Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    BMC Cancer. 2017;17:492.
    PubMed     Text format     Abstract available


  182. KIM EY, Jung JY, Kim A, Kim K, et al
    Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
    BMC Cancer. 2017;17:467.
    PubMed     Text format     Abstract available


  183. ZHOU Q, Song Y, Zhang X, Chen GY, et al
    A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    BMC Cancer. 2017;17:462.
    PubMed     Text format     Abstract available


    June 2017
  184. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Text format     Abstract available


  185. SNEDDON S, Patch AM, Dick IM, Kazakoff S, et al
    Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    BMC Cancer. 2017;17:396.
    PubMed     Text format     Abstract available


    May 2017
  186. JOHNEN G, Gawrych K, Raiko I, Casjens S, et al
    Calretinin as a blood-based biomarker for mesothelioma.
    BMC Cancer. 2017;17:386.
    PubMed     Text format     Abstract available


  187. MISUMI Y, Okamoto H, Sasaki J, Masuda N, et al
    Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    BMC Cancer. 2017;17:377.
    PubMed     Text format     Abstract available


  188. KULASINGHE A, Perry C, Kenny L, Warkiani ME, et al
    PD-L1 expressing circulating tumour cells in head and neck cancers.
    BMC Cancer. 2017;17:333.
    PubMed     Text format     Abstract available


  189. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Text format     Abstract available


  190. YEO J, Crawford EL, Zhang X, Khuder S, et al
    A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    BMC Cancer. 2017;17:301.
    PubMed     Text format     Abstract available


  191. NAKAMURA K, Kato M, Shukuya T, Mori K, et al
    Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    BMC Cancer. 2017;17:302.
    PubMed     Text format     Abstract available


  192. SHIMAZU K, Tada Y, Morinaga T, Shingyoji M, et al
    Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC Cancer. 2017;17:309.
    PubMed     Text format     Abstract available


  193. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Text format     Abstract available


    April 2017
  194. OHSAKI Y, Sasaki T, Endo S, Kitada M, et al
    Observation of Zn-photoprotoporphyrin red Autofluorescence in human bronchial cancer using color-fluorescence endoscopy.
    BMC Cancer. 2017;17:289.
    PubMed     Text format     Abstract available


  195. ZHOU T, Zhan J, Fang W, Zhao Y, et al
    Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).
    BMC Cancer. 2017;17:269.
    PubMed     Text format     Abstract available


  196. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Text format     Abstract available


  197. HORIMASU Y, Ishikawa N, Tanaka S, Hirano C, et al
    MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
    BMC Cancer. 2017;17:263.
    PubMed     Text format     Abstract available


  198. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Text format     Abstract available


  199. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Text format     Abstract available


    March 2017
  200. FRUGTNIET BA, Martin TA, Zhang L, Jiang WG, et al
    Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.
    BMC Cancer. 2017;17:224.
    PubMed     Text format     Abstract available


  201. AK G, Tada Y, Shimada H, Metintas S, et al
    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    BMC Cancer. 2017;17:212.
    PubMed     Text format     Abstract available


  202. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Text format     Abstract available


  203. WANG JZ, Xiang JJ, Wu LG, Bai YS, et al
    A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    BMC Cancer. 2017;17:167.
    PubMed     Text format     Abstract available


    February 2017
  204. FERNANDEZ-MARTINEZ L, Villegas JA, Santamaria I, Pitiot AS, et al
    Identification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree.
    BMC Cancer. 2017;17:146.
    PubMed     Text format     Abstract available


  205. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Text format     Abstract available


  206. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Text format     Abstract available


    January 2017
  207. WANG L, Liu D, Lu J, Zhang S, et al
    The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy.
    BMC Cancer. 2017;17:75.
    PubMed     Text format     Abstract available


  208. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Text format     Abstract available


  209. GOTO T, Hirotsu Y, Mochizuki H, Nakagomi T, et al
    Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.
    BMC Cancer. 2017;17:65.
    PubMed     Text format     Abstract available


  210. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Text format     Abstract available


  211. MARRER E, Jolly D, Arveux P, Lejeune C, et al
    Incidence of solitary pulmonary nodules in Northeastern France: a population-based study in five regions.
    BMC Cancer. 2017;17:47.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: